HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PLx Pharma Proposes “GI-Safer” OTC Aspirin In New Drug Application

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm files a rare new drug application for an OTC product, a formulation of aspirin and phosphatidylcholine designed to be more tolerable to the gastrointestinal tract. The involvement of OTC veterans Peter Mann and Michael Valentino on PLx’s board suggests strong market potential.

You may also be interested in...



PLx Pharma Saturates Health Care Providers With Marketing For Liquid-Filled Vazalore Aspirin

PLx says Vazalore, only liquid-filled OTC aspirin in the US, had strong sales growth since launch in 30,000 stores. It plans second phase of rollout and promotions to expand outreach to cardiologists and patients.

Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition

On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch

FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule

FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS125113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel